Skip to main content
IRLAB Therapeutics logo

IRLAB Therapeutics — Investor Relations & Filings

Ticker · IRLAB ISIN · SE0012675361 LEI · 549300JAT34LHEI0DH60 ST Manufacturing
Open in API
Filings indexed 157 across all filing types
Latest filing 2023-05-10 Interim / Quarterly Rep…
Country SE Sweden
Listing ST IRLAB

About IRLAB Therapeutics

https://irlab.se/

IRLAB Therapeutics is a research and development company that discovers and develops novel treatments for neurodegenerative diseases, with a primary focus on Parkinson's disease and other central nervous system (CNS) disorders. The company's research originates from Nobel Prize-winning science and is driven by its proprietary Integrative Screening Process (ISP) platform. This systems pharmacology-based discovery engine utilizes an extensive database to generate a pipeline of drug candidates. The company's portfolio includes clinical-stage assets such as Mesdopetam (IRL790), in development for treating levodopa-induced dyskinesia (LIDs), and Pirepemat (IRL752), which is being developed to reduce falls and improve balance in patients with Parkinson's disease.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for the period January–March 2023 for IRLAB Therapeutics. It contains comprehensive financial statements, a summary of the quarter, management commentary (VD har ordet), and operational updates. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis. Q1 2023
2023-05-10 Swedish
Interim / Quarterly Report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report January – March 2023' for IRLAB Therapeutics. It contains comprehensive financial statements, including a financial summary table with comparative data for the period, as well as detailed management commentary on business operations, clinical trial progress, and strategic outlook. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2023
2023-05-10 English
IRLAB kommenterar uppgifter i Ipsens Universella registreringsdokument 2022 och mesdopetams fortsatta utveckling
Regulatory Filings Classification · 100% confidence The document is a press release dated May 3, 2023, from IRLAB Therapeutics AB. It addresses an inaccuracy found in Ipsen's Universal Registration Document 2022 regarding the transfer of development and commercialization rights for the drug candidate mesdopetam. The text discusses ongoing discussions, regulatory status (ready for Phase III), and provides contact information, concluding with a statement that the information is being made public under the EU Market Abuse Regulation. This type of announcement, correcting or clarifying information related to ongoing business or regulatory matters, fits best under the general category for regulatory announcements that don't fit specific financial reports or insider trading rules. Since it is a formal, time-sensitive public disclosure mandated by market rules, and it is not a full financial report (10-K, IR), earnings release (ER), or a specific legal/director action, the most appropriate classification is Regulatory Filings (RNS), which serves as a general regulatory announcement fallback.
2023-05-03 Swedish
IRLAB comments on statements in Ipsen’s 2022 Universal Registration Document and the further development of mesdopetam
Regulatory Filings Classification · 95% confidence The document is a press release dated May 3, 2023, from IRLAB Therapeutics AB. It addresses incorrect information published by Ipsen in their '2022 Universal Registration Document' regarding the transfer of rights for the drug mesdopetam. The text is a direct commentary and clarification on a legal/commercial matter involving another company's filing. It is not a full financial report (10-K, IR), an earnings release (ER), or a formal legal proceeding report (LTR), but rather a specific announcement correcting public information related to a collaboration agreement. Since it deals with a specific, non-standard corporate event (a correction regarding a collaboration/licensing agreement and rights transfer), and it is presented as a 'Press Release', the most appropriate general category that captures specific corporate announcements not covered by the primary financial/governance forms is 'Regulatory Filings' (RNS), which serves as a broad category for official regulatory disclosures that aren't otherwise classified. It is too specific for RNS, but given the options, it is a regulatory disclosure correcting a prior filing. It is not a Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP). It is a specific corporate update, best categorized as RNS as a catch-all for significant, non-standard regulatory announcements.
2023-05-03 English
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 100% confidence FY 2022
2023-04-28 Swedish
Annual Report (ESEF) 2022
Annual Report (ESEF) Classification · 100% confidence FY 2022
2023-04-28 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.